[go: up one dir, main page]

MX2013005187A - Composicion farmaceutica y forma galenica y forma galenica a base de drodedarona y su procedimiento de preparacion. - Google Patents

Composicion farmaceutica y forma galenica y forma galenica a base de drodedarona y su procedimiento de preparacion.

Info

Publication number
MX2013005187A
MX2013005187A MX2013005187A MX2013005187A MX2013005187A MX 2013005187 A MX2013005187 A MX 2013005187A MX 2013005187 A MX2013005187 A MX 2013005187A MX 2013005187 A MX2013005187 A MX 2013005187A MX 2013005187 A MX2013005187 A MX 2013005187A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
dosage form
dronedarone
oral administration
preparation
Prior art date
Application number
MX2013005187A
Other languages
English (en)
Inventor
Bernard Abramovici
Stephane Beilles
Jean-Claude Gautier
Sandra Chambonnet
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2013005187A publication Critical patent/MX2013005187A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere, de una manera general, a una composición farmacéutica para administración oral que contiene como principio activo un derivado de benzofurano con actividad antiarrítmica, en particular dronedarona y sus sales farmacéuticamente aceptables y al menos un excipiente lipídico, estando destinada tal composición farmacéutica en una forma galénica de tipo cápsula, en particular de envoltura dura. Esta composición farmacéutica y tal forma galénica que comprende tal composición tienen por objeto limitar el efecto comida después de la administración oral en el humano. El excipiente lipídico permite por una parte solubilizar el principio activo conforme a la invención y por otra parte evitar los efectos negativos del pH a nivel del tracto intestinal, permitiendo así exonerar el efecto comida de forma significativa.
MX2013005187A 2010-11-10 2011-11-10 Composicion farmaceutica y forma galenica y forma galenica a base de drodedarona y su procedimiento de preparacion. MX2013005187A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1059306A FR2967067A1 (fr) 2010-11-10 2010-11-10 Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation
PCT/FR2011/052622 WO2012063005A2 (fr) 2010-11-10 2011-11-10 Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation

Publications (1)

Publication Number Publication Date
MX2013005187A true MX2013005187A (es) 2013-07-03

Family

ID=44072520

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005187A MX2013005187A (es) 2010-11-10 2011-11-10 Composicion farmaceutica y forma galenica y forma galenica a base de drodedarona y su procedimiento de preparacion.

Country Status (24)

Country Link
US (2) US9018250B2 (es)
EP (1) EP2637645B1 (es)
JP (1) JP2013542244A (es)
KR (1) KR20140091646A (es)
CN (1) CN103347502B (es)
AU (1) AU2011327910A1 (es)
BR (1) BR112013011763A2 (es)
CA (1) CA2817310A1 (es)
CY (1) CY1120418T1 (es)
DK (1) DK2637645T3 (es)
ES (1) ES2670445T3 (es)
FR (1) FR2967067A1 (es)
HR (1) HRP20180793T1 (es)
HU (1) HUE037446T2 (es)
IL (1) IL226183A0 (es)
LT (1) LT2637645T (es)
MX (1) MX2013005187A (es)
PL (1) PL2637645T3 (es)
PT (1) PT2637645T (es)
RU (1) RU2013126431A (es)
SG (1) SG190240A1 (es)
SI (1) SI2637645T1 (es)
TR (1) TR201807058T4 (es)
WO (1) WO2012063005A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2967067A1 (fr) * 2010-11-10 2012-05-11 Sanofi Aventis Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation
CN103126994B (zh) * 2011-12-05 2017-03-29 北京虹湾医药技术有限公司 含决奈达隆的固体药物组合物
JP6049409B2 (ja) * 2012-11-08 2016-12-21 中日本カプセル 株式会社 ハードカプセルの製造方法
CN105412027B (zh) * 2015-11-13 2018-10-26 青岛市海慈医疗集团 一种盐酸决奈达隆片剂的制备方法
CN112137999A (zh) * 2020-09-30 2020-12-29 郑州大学 盐酸决奈达隆在制备抗消化道肿瘤药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3248401A (en) 1966-04-26 Diethylaminoe hoxybenzoyl benzofurans
US4806663A (en) 1987-04-06 1989-02-21 The University Of Tennessee Research Corporation Certain 3-substituted 2-alkyl benzofuran derivatives
US4851554A (en) 1987-04-06 1989-07-25 University Of Tennessee Research Corporation Certain 3-substituted 2-alkyl benzofuran derivatives
US4831054A (en) 1988-04-18 1989-05-16 Taro Pharmaceuticals, Ltd. 2-Alkyl-3-benzoylbenzofurans useful for treating cardiac arrhythmia
AT391316B (de) 1988-09-15 1990-09-25 Ebewe Arzneimittel Neue thienyloxy-alkylamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5364880A (en) 1993-06-16 1994-11-15 Advanced Therapies, Inc. Compound for treatment of cardiac arrhythmia, synthesis, and methods of use
FR2764800B1 (fr) * 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
FR2813306B1 (fr) 2000-08-23 2005-10-21 Sanofi Synthelabo Aminoalkybenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation et les compositions les contenant
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
ITRM20030074A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Formulazioni semisolide a rilascio immediato intese
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
KR100921947B1 (ko) * 2003-11-19 2009-10-15 (주)아모레퍼시픽 피부 미백 화장료 조성물
WO2008063323A2 (en) 2006-10-13 2008-05-29 Reliant Pharmaceuticals, Inc. Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof
CN102188417A (zh) * 2010-03-19 2011-09-21 江苏恒瑞医药股份有限公司 决奈达隆药物组合物
FR2967067A1 (fr) * 2010-11-10 2012-05-11 Sanofi Aventis Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation

Also Published As

Publication number Publication date
SG190240A1 (en) 2013-06-28
CN103347502B (zh) 2017-04-26
IL226183A0 (en) 2013-07-31
US9018250B2 (en) 2015-04-28
TR201807058T4 (tr) 2018-06-21
FR2967067A1 (fr) 2012-05-11
BR112013011763A2 (pt) 2016-09-13
EP2637645B1 (fr) 2018-02-21
WO2012063005A3 (fr) 2012-09-13
ES2670445T3 (es) 2018-05-30
CA2817310A1 (fr) 2012-05-18
EP2637645A2 (fr) 2013-09-18
HUE037446T2 (hu) 2018-09-28
US20150196528A1 (en) 2015-07-16
US20130245115A1 (en) 2013-09-19
DK2637645T3 (en) 2018-06-06
WO2012063005A2 (fr) 2012-05-18
KR20140091646A (ko) 2014-07-22
CY1120418T1 (el) 2019-07-10
JP2013542244A (ja) 2013-11-21
CN103347502A (zh) 2013-10-09
SI2637645T1 (en) 2018-06-29
HRP20180793T1 (hr) 2018-06-29
PL2637645T3 (pl) 2018-08-31
LT2637645T (lt) 2018-06-11
RU2013126431A (ru) 2014-12-20
AU2011327910A1 (en) 2013-05-30
PT2637645T (pt) 2018-05-24

Similar Documents

Publication Publication Date Title
NZ602510A (en) Treatment of lupus nephritis using laquinimod
WO2012079092A3 (en) Testosterone undecanoate compositions
EA201590835A1 (ru) Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием
PE20142353A1 (es) Ansolvatos de sal de noribogaina
UA106634C2 (uk) Тверда фармацевтична дозована форма
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
MX2013005187A (es) Composicion farmaceutica y forma galenica y forma galenica a base de drodedarona y su procedimiento de preparacion.
CL2014002935A1 (es) Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador
PH12014501408A1 (en) Immediate release multi unit pellet system
PH12015500823A1 (en) Modified release formulations for oprozomib
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
PH12014502836A1 (en) Medicament form for release of active ingredients
WO2012053768A3 (en) Aryloxyphenoxyacetyl-based compound having hif-1 inhibition activity, preparation method thereof and pharmaceutical composition containing the same as an active ingredient
MX346316B (es) Formulacion farmaceutica o nutraceutica.
WO2012064159A3 (ko) 항암용 조성물
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
MX2008011020A (es) Compuestos de receptor sigma.
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
NZ701274A (en) Oral b12 therapy
EA201100616A1 (ru) Новые формы применения цинеола
RU2013144966A (ru) Композиция, содержащая диаминоксидазу, для применения для лечения или предотвращения фибромиалгии или синдрома хронической усталости
JP2012041314A5 (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal